Literature DB >> 11579319

Impaired exercise performance after successful liver transplantation.

A L Stephenson1, E M Yoshida, R T Abboud, G Fradet, R D Levy.   

Abstract

BACKGROUND: Recipients of heart, lung, and kidney transplants have impaired peak exercise performance (peak Vo2 40% to 60% predicted, reduced anaerobic threshold [AT]) without evidence of ventilatory or cardiac limitations. The aim of this study was to determine whether similar exercise impairment occurs in liver transplant recipients.
METHODS: We studied eight healthy liver transplant recipients (age 42+/-9 [SD] years, 6 male, 31+/-13 months posttransplant). Immunosuppression included FK506 or cyclosporine, azathioprine or mycophenolate mofetil, and prednisone. Subjects underwent lung function testing and cardiopulmonary exercise testing on a cycle ergometer.
RESULTS: Peak exercise oxygen consumption (Vo2) was 22+/-8 ml/min/kg (66+/-20% predicted maximum). No subject demonstrated exercise desaturation or ventilatory limitation (peak minute ventilation 55+/-8% predicted maximum voluntary ventilation). Peak heart rate was 87+/-8% of predicted maximum. Early AT was evident (1.2+/-0.34 L/min, 48+/-11% predicted Vo2max).
CONCLUSIONS: Liver transplant recipients exhibit impaired peak exercise performance similar to that observed after other solid organ transplants, possibly as a result of chronic deconditioning or myopathy related to immunosuppressive medications.

Entities:  

Mesh:

Year:  2001        PMID: 11579319     DOI: 10.1097/00007890-200109270-00032

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  2 in total

1.  Metabolic syndrome after liver transplantation: preventable illness or common consequence?

Authors:  Eric R Kallwitz
Journal:  World J Gastroenterol       Date:  2012-07-28       Impact factor: 5.742

2.  Physical fitness, fatigue, and quality of life after liver transplantation.

Authors:  Berbke T J van Ginneken; Rita J G van den Berg-Emons; Geert Kazemier; Herold J Metselaar; Hugo W Tilanus; Henk J Stam
Journal:  Eur J Appl Physiol       Date:  2007-03-16       Impact factor: 3.078

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.